Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus
- PMID: 39027720
- PMCID: PMC11254743
- DOI: 10.1016/j.jtauto.2024.100246
Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus
Abstract
Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a variety of disease symptoms and an unpredictable clinical course. To improve treatment outcome, stratification based on immunological manifestations commonly seen in patients with SLE such as autoantibodies, type I interferon (IFN) signature and neutrophil extracellular trap (NET) release may help. It is assumed that there is an association between these immunological phenomena, since NET release induces IFN production and IFN induces autoantibody formation via B-cell activation. Here we studied the association between autoantibodies, the IFN signature, NET release, and clinical manifestations in patients with SLE.
Methods: We performed principal component analysis (PCA) and hierarchical clustering of 57 SLE-related autoantibodies in 25 patients with SLE. We correlated each autoantibody to the IFN signature and NET inducing capacity.
Results: We observed two distinct clusters: one cluster contained mostly patients with a high IFN signature. Patients in this cluster often present with cutaneous lupus, and have higher anti-dsDNA concentrations. Another cluster contained a mix of patients with a high and low IFN signature. Patients with high and low NET inducing capacity were equally distributed between the clusters. Variance between the clusters is mainly driven by antibodies against histones, RibP2, RibP0, EphB2, RibP1, PCNA, dsDNA, and nucleosome. In addition, we found a trend towards increased concentrations of autoantibodies against EphB2, RibP1, and RNP70 in patients with an IFN signature. We found a negative correlation of NET inducing capacity with anti-FcER (r = -0.530; p = 0.007) and anti-PmScl100 (r = -0.445; p = 0.03).
Conclusion: We identified a subgroup of patients with an IFN signature that express increased concentrations of antibodies against DNA and RNA-binding proteins, which can be useful for further patient stratification and a more targeted therapy. We did not find positive associations between autoantibodies and NET inducing capacity. Our study further strengthens the evidence of a correlation between RNA-binding autoantibodies and the IFN signature.
Keywords: Autoantibodies; Interferon signature; NETosis; Patient stratification; Systemic lupus erythematosus.
© 2024 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




Similar articles
-
Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities.Immunol Lett. 2015 Dec;168(2):254-9. doi: 10.1016/j.imlet.2015.09.016. Epub 2015 Oct 3. Immunol Lett. 2015. PMID: 26434792
-
Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.Arthritis Rheumatol. 2015 Dec;67(12):3190-200. doi: 10.1002/art.39296. Arthritis Rheumatol. 2015. PMID: 26245802 Clinical Trial.
-
Identification and stratification of systemic lupus erythematosus patients into two transcriptionally distinct clusters based on IFN-I signature.Lupus. 2021 Apr;30(5):762-774. doi: 10.1177/0961203321990107. Epub 2021 Jan 26. Lupus. 2021. PMID: 33497307
-
Optimal Selection of IFN-α-Inducible Genes to Determine Type I Interferon Signature Improves the Diagnosis of Systemic Lupus Erythematosus.Biomedicines. 2023 Mar 12;11(3):864. doi: 10.3390/biomedicines11030864. Biomedicines. 2023. PMID: 36979843 Free PMC article. Review.
-
An Emerging Role for Anti-DNA Antibodies in Systemic Lupus Erythematosus.Int J Mol Sci. 2023 Nov 19;24(22):16499. doi: 10.3390/ijms242216499. Int J Mol Sci. 2023. PMID: 38003689 Free PMC article. Review.
Cited by
-
Mechanistic Evaluation of Anti-CD19 CAR-T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model.Clin Transl Sci. 2025 Feb;18(2):e70146. doi: 10.1111/cts.70146. Clin Transl Sci. 2025. PMID: 39936636 Free PMC article.
References
-
- Gatto M., Zen M., Iaccarino L., Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat. Rev. Rheumatol. 2019;15:30–48. - PubMed
-
- Rodriguez-Almaraz E., Gutierrez-Solis E., Rabadan E., Rodriguez P., Carmona L., Morales E., Galindo M. Something new about prognostic factors for lupus nephritis? A systematic review. Lupus. 2021;30:2256–2267. - PubMed
-
- Toro-Dominguez D., Martorell-Marugan J., Goldman D., Petri M., Carmona-Saez P., Alarcon-Riquelme M.E. Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression. Arthritis Rheumatol. 2018;70:2025–2035. - PMC - PubMed
-
- Kariuki S.N., Franek B.S., Kumar A.A., Arrington J., Mikolaitis R.A., Utset T.O., et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res. Ther. 2010;12 - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous